Shire on hold by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell reiterated Shire Pharmaceuticals Group plc at hold as the companies second-quarter revenues rose 3% to $439 million, compared to Jefferies' projected $464 million. The company's product sales were up 7% at $376 million and included Adderall sales of $230 million, below the analyst's forecast of $392 million in sales including Adderall sales of $235 million. Shares of the Basingstoke, England-based pharmaceutical company were up 2p, or 0.24, at 840p on volume of 6,660,824 shares versus the three-month running average of 4,660,824 shares. (LSE: SHP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.